EDP-305 1.5 mg + EDP-305 2 mg + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Steatohepatitis
Conditions
Non-Alcoholic Steatohepatitis
Trial Timeline
Jan 27, 2020 → Nov 30, 2021
NCT ID
NCT04378010About EDP-305 1.5 mg + EDP-305 2 mg + Placebo
EDP-305 1.5 mg + EDP-305 2 mg + Placebo is a phase 2 stage product being developed by Enanta Pharmaceuticals for Non-Alcoholic Steatohepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04378010. Target conditions include Non-Alcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04378010 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-Alcoholic Steatohepatitis